Valneva SE ADR (VALN)

NASDAQ
Currency in USD
6.35
-0.11(-1.71%)
Closed·
After Hours
6.29-0.06(-0.94%)
·
VALN Scorecard
Full Analysis
Quickly burning through cash
Earnings results expected in 7 days
Fair Value
Day's Range
6.176.49
52 wk Range
3.629.50
Key Statistics
Edit
Prev. Close
6.45
Open
6.44
Day's Range
6.17-6.49
52 wk Range
3.62-9.5
Volume
14.9K
Average Volume (3m)
76.71K
1-Year Change
-16.12%
Book Value / Share
1.16
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VALN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.30
Upside
+125.20%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Valneva SE ADR Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate which is in Phase III clinical trial against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a Phase I vaccine candidate targeting the Zika virus (ZIKV), a mosquito-borne viral disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Compare VALN to Peers and Sector

Metrics to compare
VALN
Peers
Sector
Relationship
P/E Ratio
−39.4x−2.1x−0.5x
PEG Ratio
−0.45−0.030.00
Price/Book
2.7x1.5x2.6x
Price / LTM Sales
2.8x9.0x2.9x
Upside (Analyst Target)
148.1%201.2%56.4%
Fair Value Upside
Unlock1.0%9.3%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.30
(+125.20% Upside)

Earnings

Latest Release
Mar 20, 2025
EPS / Forecast
-0.3655 / -0.1957
Revenue / Forecast
60.34M / 60.22M
EPS Revisions
Last 90 days

FAQ

What Is the Valneva SE (VALN) Stock Price Today?

The Valneva SE stock price today is 6.35

What Stock Exchange Does Valneva SE Trade On?

Valneva SE is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Valneva SE?

The stock symbol for Valneva SE is "VALN."

What Is the Valneva SE Market Cap?

As of today, Valneva SE market cap is 556.93M.

What is Valneva SE Earnings Per Share?

The Valneva SE EPS is -0.08.

What Is the Next Valneva SE Earnings Date?

Valneva SE will release its next earnings report on 06 May 2025.

From a Technical Analysis Perspective, Is VALN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.